Cover Image
市場調查報告書

膠質母細胞瘤:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Glioblastoma multiforme: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365177
出版日期 內容資訊 英文 144 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
膠質母細胞瘤:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Glioblastoma multiforme: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 144 Pages
簡介

本報告提供膠質母細胞瘤治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

治療:膠質母細胞瘤

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:膠質母細胞瘤

  • 摘要整理
  • 疾病定義
  • 全球變動
  • 危險因素
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點
  • 參考文獻

上市藥:膠質母細胞瘤

  • 摘要整理
  • 產品概要
  • 產品簡介:Avastin
  • 產品簡介:Temodar

開發平台:膠質母細胞瘤

  • 摘要整理
  • 臨床實驗平台概要
  • 標靶藥物簡介
  • 臨床試驗設計
  • 最近中止開發的藥
  • 產品簡介 (後期) :DCVax-L
  • 產品簡介 (後期) :ICT-107
  • 產品簡介 (後期) :Opdivo
  • 產品簡介 (後期) :Toca 511/FC
  • 產品簡介 (後期) :VB-111

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5540

The prognosis of patients with GBM remains poor as drug developers turn to immunotherapies to provide more effective options.

This report addresses the following questions:

  • What is the current standard of care for patients with GBM in each treatment setting, and how effective are these options?
  • What are the major challenges facing drug developers in GBM?
  • How do the various PD-1 pathway inhibitors, gene therapies, and vaccines currently in development for GBM compare in terms of safety and efficacy?
  • What patient segmentations are most relevant in the treatment of GBM?

TABLE OF CONTENTS

TREATMENT: GLIOBLASTOMA MULTIFORME

  • 1. Executive Summary
  • 2. Primary Research Methodology
  • 3. Disease Definition and Diagnosis
  • 4. Patient Segmentation
  • 5. Country Treatment Trees
  • 6. Current Treatment Options
  • 7. Prescribing Trends
  • 8. Unmet Needs

EPIDEMIOLOGY: GLIOBLASTOMA MULTIFORME

  • 9. Executive Summary
  • 10. Disease Definition
  • 11. Global Variation
  • 12. Risk Factors
  • 13. Sources and Methodology
  • 14. Forecast
  • 15. Epidemiologist Insight
  • 16. Strengths and Limitations
  • 17. Bibliography

MARKETED DRUGS: GLIOBLASTOMA MULTIFORME

  • 18. Executive Summary
  • 19. Product Overview
  • 20. Product profile: Avastin
  • 21. Product profile: Temodar

PIPELINE: GLIOBLASTOMA MULTIFORME

  • 22. Executive Summary
  • 23. Clinical Pipeline Overview
  • 24. Target Product Profile
  • 25. Clinical Trial Design
  • 26. Recently Discontinued Drugs
  • 27. Product profile (late stage): DCVax-L
  • 28. Product profile (late stage): ICT-107
  • 29. Product profile (late stage): Opdivo
  • 28. Product profile (late stage): Toca 511/FC
  • 29. Product profile (late stage): VB-111
Back to Top